ASCENTAGE PHARMA Trademark

Trademark Overview


On Monday, March 14, 2022, a trademark application was filed for ASCENTAGE PHARMA with the United States Patent and Trademark Office. The USPTO has given the ASCENTAGE PHARMA trademark a serial number of 79339835. The federal status of this trademark filing is REGISTERED as of Tuesday, November 7, 2023. This trademark is owned by Jiangsu Ascentage Pharma Inc.. The ASCENTAGE PHARMA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and medical research services, namely, studies for combined compound functional mechanism on animals; cancer research for medical purposes; pharmaceutical research and development, namely, early evaluation for implementation of the new drugs; pharmaceutical research; scientific surveys for medical purposes; chemical analysis services; research and analysis in the field of biochemistry; chemical research service; scientific and medical research services in the nature of chemical analysis assessment service; chemical research and analysis; scientific and medical research services in the nature of chemical synthesis assessment service; chemical analysis; chemistry consulting services; chemical research; cosmetic research; structural and functional analysis of genomes; stem cell research services; biotechnological research; blood analysis service; genetic screening for scientific purposes; biological cloning services; research and development of antibodies; genetic testing for s...
ascentage pharma

General Information


Serial Number79339835
Word MarkASCENTAGE PHARMA
Filing DateMonday, March 14, 2022
Status700 - REGISTERED
Status DateTuesday, November 7, 2023
Registration Number7209445
Registration DateTuesday, November 7, 2023
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, August 22, 2023

Trademark Statements


NOT AVAILABLE"PHARMA"
Goods and ServicesScientific and medical research services, namely, studies for combined compound functional mechanism on animals; cancer research for medical purposes; pharmaceutical research and development, namely, early evaluation for implementation of the new drugs; pharmaceutical research; scientific surveys for medical purposes; chemical analysis services; research and analysis in the field of biochemistry; chemical research service; scientific and medical research services in the nature of chemical analysis assessment service; chemical research and analysis; scientific and medical research services in the nature of chemical synthesis assessment service; chemical analysis; chemistry consulting services; chemical research; cosmetic research; structural and functional analysis of genomes; stem cell research services; biotechnological research; blood analysis service; genetic screening for scientific purposes; biological cloning services; research and development of antibodies; genetic testing for scientific research purposes; bacteriological research and analysis; biomedical research; medical research; pharmaceutical drug development; medical laboratory service; development of pharmaceutical preparations and pharmaceuticals; medical research service; biological research and analysis; bacteriological research; biological research; scientific and medical research, namely conducting clinical trials for others; computer programming of medical aspects; scientific and technical services, namely, testing and evaluation of pharmaceuticals; pharmaceutical research
Description of MarkThe mark consists of a stylized letter A incorporating a curved band to the left of the stylized wording ASCENTAGE PHARMA.

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, May 6, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameASCENTAGE PHARMA (SUZHOU) CO., LTD.
Party Type31 - New Owner After Registration
Legal Entity Type98 - Unknown
AddressCN

Party NameJiangsu Ascentage Pharma Inc.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressCN

Party NameJiangsu Ascentage Pharma Inc.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCN

Party NameJiangsu Ascentage Pharma Inc.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCN

Trademark Events


Event DateEvent Description
Thursday, May 5, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, May 6, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 10, 2022APPLICATION FILING RECEIPT MAILED
Sunday, December 25, 2022ASSIGNED TO EXAMINER
Monday, December 26, 2022NON-FINAL ACTION WRITTEN
Tuesday, December 27, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, February 22, 2023REFUSAL PROCESSED BY MPU
Wednesday, February 22, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, March 15, 2023REFUSAL PROCESSED BY IB
Wednesday, July 12, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, July 12, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 13, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 2, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 2, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 2, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Monday, August 21, 2023NOTIFICATION PROCESSED BY IB
Tuesday, August 22, 2023PUBLISHED FOR OPPOSITION
Tuesday, August 22, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, October 11, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, October 11, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, October 31, 2023NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, November 7, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, November 7, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Wednesday, February 7, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, February 8, 2024FINAL DISPOSITION PROCESSED
Thursday, February 8, 2024FINAL DISPOSITION NOTICE SENT TO IB
Monday, February 26, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, February 26, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, February 26, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 4, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, August 21, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, August 21, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, August 21, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 21, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 21, 2025TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Thursday, August 21, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, November 7, 2025CHANGE OF OWNER RECEIVED FROM IB